Not independent
Tenure on this board
11.5 yrs
Also a director at
Engene Therapeutics Inc (ENGN)
Meeting calendar
REPL · Annual meeting · Wednesday, September 3, 2025
Replimune Group Inc
5 nominees · 4 ballot items.
Election of five Class I directors; ratification of PwC as the independent registered public accounting firm for the fiscal year ending March 31, 2026; advisory Say-on-Pay on compensation of named executive officers for the fiscal year ended March 31, 2025; and approval of an amendment to the 2018 Omnibus Plan increasing the evergreen share reserve from 4% to 5% of outstanding shares.
Market cap
$942M
1Y TSR
+2.4%
Board grade
C-
Record date
Jul 16, 2025
Filing
DEF 14A
Meeting concluded · Sep 3, 2025
Follow how the vote landed and what changed on Replimune Group Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot4
- 1
Election of Class I Directors
ManagementBoard: FORTo elect five Class I directors to serve a three-year term until the Company’s 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
- 2
Ratification of the Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the Audit Committee’s selection of PricewaterhouseCoopers LLP as Replimune’s independent registered public accounting firm for the fiscal year ending March 31, 2026.
- 3
Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers
ManagementBoard: FORSay-on-Pay advisory vote on the compensation of the Company’s named executive officers for the fiscal year ended March 31, 2025.
- 4
Approval of an Amendment to the Company’s 2018 Omnibus Incentive Compensation Plan
ManagementBoard: FORPlan Amendment to revise the Evergreen Provision from 4% to 5% of outstanding shares; Board has approved the Plan Amendment subject to stockholder approval.
Director elections
Nominees on the ballot5
Independent
Tenure on this board
9.0 yrs
Also a director at
Black Diamond Therapeutics Inc (BDTX)
Independent
Tenure on this board
1.3 yrs
Also a director at
Dbv Technologies SA (DBVT)
Independent
Tenure on this board
4.6 yrs
Also a director at
Karyopharm Therapeutics Inc (KPTI)Vera Therapeutics Inc (VERA)Nuvalent Inc (NUVL)
Independent
Tenure on this board
8.8 yrs
Also a director at
Cvrx Inc (CVRX)Imagenebio Inc (IMA)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 13.2% | 11,045,336 | $84M |
| 2 | PRICE T ROWE ASSOCIATES INC /MD/ | 9.5% | 7,971,382 | $61M |
| 3 | RTW INVESTMENTS, LP | 8.8% | 7,356,916 | $56M |
| 4 | SUVRETTA CAPITAL MANAGEMENT, LLC | 5.0% | 4,221,836 | $32M |
| 5 | STATE STREET CORP | 4.5% | 3,782,237 | $29M |
| 6 | BlackRock, Inc. | 3.9% | 3,239,115 | $25M |
| 7 | FCPM III SERVICES B.V. | 3.3% | 2,808,368 | $21M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 2,759,120 | $21M |
| 9 | D. E. Shaw Co., Inc.Activist | 2.7% | 2,262,138 | $17M |
| 10 | BlackRock, Inc. | 2.7% | 2,238,678 | $17M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Replimune Group Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Reference
Frequently asked questions
- When is the Replimune Group Inc 2025 annual meeting?
- Replimune Group Inc (REPL) holds its 2025 annual shareholder meeting on Wednesday, September 3, 2025.
- What is the record date for the Replimune Group Inc 2025 meeting?
- The record date for the Replimune Group Inc 2025 meeting is Wednesday, July 16, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Replimune Group Inc's 2025 meeting?
- The board is presenting 5 director nominees at the Replimune Group Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Replimune Group Inc 2025 meeting?
- Shareholders will vote on 4 proposals at the Replimune Group Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.